Gilead Sciences stock focuses on liver data in week ahead

Published on 11/01/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock heads into a week of liver-disease data in Denver. The program covers PBC and hepatitis delta research.

Gilead's Liver Data Set The Tone

The Liver Meeting in Denver runs from November 5 through November 9, 2026.
Gilead plans presentations on primary biliary cholangitis and chronic hepatitis delta.
The program includes late-breaking Phase 3 research on Livdelzi and long-term evidence for Hepcludex.

Gilead Sciences, US3755581036, Illustration mit AI erstellt.

Gilead Sciences will present new clinical and real-world evidence at The Liver Meeting 2026 in Denver from Thursday, November 5, through Monday, November 9. The company announced the program on October 22 in a Gilead news release.

The research covers primary biliary cholangitis, or PBC, and chronic hepatitis delta virus infection. Gilead said its scientific program includes 21 accepted abstracts, spanning late-breaking Phase 3 research for Livdelzi, also known as seladelpar, and long-term and real-world evidence for Hepcludex, or bulevirtide.

Late-Breaking PBC Results Lead

The most prominent PBC item is the late-breaking IDEAL Phase 3 presentation on composite alkaline phosphatase normalization with Livdelzi. Abstract 5007 is scheduled as an oral presentation on Sunday, November 8, from 5:00 to 5:15 p.m. Denver time.

Additional Livdelzi presentations address five-year safety and efficacy, fatigue, renal function, inflammatory and fibrotic pathways, treatment adherence and real-world factors affecting access to second-line treatment. The company said the data are intended to broaden the view of treatment response and long-term disease management.

Hepatitis Delta Evidence Expands

Gilead also plans several analyses of Hepcludex in chronic hepatitis delta. Topics include integrated efficacy findings, portal hypertension after 48 weeks of treatment, disease progression, non-invasive fibrosis testing and low testing rates among people with chronic hepatitis B.

For investors, the meeting offers a scheduled readout on clinical development and patient outcomes rather than a new earnings date. The relevance to the business will depend on how the presented evidence affects expectations for Livdelzi and Hepcludex in their respective markets.

Gilead Sciences stock traded at 152.76 euros on Lang & Schwarz at 17:21 CET on Sunday, November 1, 1.01 percent below the Xetra close of Friday, October 30. The real-time quote of Gilead Sciences stock provides the latest trading view.